Also, in this subgroup, we analyzed the response rate to treatment with HMAs between patients with and without TET2 mutations, the results showed that when comparing patients with and without TET2 mutations, the pooled OR for the response rate was 1.73 (95%CI: 1.11-2.7, P=0.016, I2=0.0%), which suggested that TET2 mutations might predict the of response to HMAs in patients with MDS patients (Figure 3b). Here, TET2 is linked to myelodysplastic syndrome.